Alcyomics

Alcyomics is a private, revenue-generating biotechnology service provider leveraging its patented Skimune® platform, a human skin explant assay, to predict immunotoxicity and efficacy for pharmaceuticals, cosmetics, and chemicals. Founded on over 30 years of academic research in graft-versus-host disease (GvHD), the company has validated its assay with >80% clinical correlation and now offers highly customizable testing services to help clients reduce development costs and animal testing. Operating from Newcastle upon Tyne, Alcyomics targets the growing market for human-relevant, non-animal testing solutions across multiple sectors including immunology, dermatology, and advanced therapies.

Skimune®: A patented, non-artificial human skin explant assay that preserves native tissue architecture and immune components to predict adverse immune reactions (e.g., immunotoxicity) and efficacy for pharmaceuticals, cosmetics, chemicals, and advanced therapies.

Alcyomics competes in the preclinical CRO and non-animal testing market. Direct competitors include other companies offering human tissue-based assays or complex in vitro models. It also faces competition from organ-on-a-chip companies (e.g., Emulate, Mimetas) and sophisticated in silico modeling firms. Its key differentiator is the use of non-artificial, full-thickness human skin explants, offering unique advantages for modeling cutaneous and systemic immune responses.